Global X Robotics and Artificial Intelligence ETF vs Koninklijke Philips NV — how do they compare? Global X Robotics and Artificial Intelligence ETF trades at $36.07, while Koninklijke Philips NV trades at $26.45 (market cap $25.47B). The key difference: Koninklijke Philips NV pays a 3.89% dividend while Global X Robotics and Artificial Intelligence ETF pays none, and Global X Robotics and Artificial Intelligence ETF is trading nearer its 52-week high, Koninklijke Philips NV nearer its low. Which is the better fit depends on your goals.
| BOTZ | PHG | |
|---|---|---|
52-Week High | $41.63 | $32.91 |
52-Week Low | $31.99 | $24.11 |
Market Cap | — | $25.47B |
Sector | — | Health |
Enterprise Value | — | $31.74B |
Dividend Yield | — | 3.89% |
Signals from Pluang's Aura AI — not financial advice
BOTZ trades at $35.87, down 2.82% with a bearish technical outlook showing 16 sell signals versus 3 buy signals. The ETF faces headwinds despite positive industry sentiment around robotics and AI growth. Recent news highlights robotics as the next frontier beyond chatbots, with humanoid robots projected to become a multi-trillion dollar market. The fund's technical indicators suggest near-term pressure with key support at $35.
The robotics and AI theme offers long-term growth potential as industrial automation and physical AI gain traction, though current technical weakness and market volatility present near-term risks. Positive industry catalysts include reshoring trends and AI's expansion into physical applications, but investors face sector rotation risks and competitive ETF landscape challenges.
PHG trades at $27.34, down 0.22% on the day, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operating cash flow of $1.17B. Recent FDA clearances for AI-powered medical devices and strategic healthcare partnerships demonstrate innovation momentum.
The stock presents a mixed outlook with 41% analyst buy ratings but bearish technical indicators. Key opportunities include AI healthcare adoption and margin expansion, while risks involve competitive pressures and debt levels. Valuation appears reasonable with P/E of 24.01 and P/S of 1.31, but requires monitoring of execution against growth expectations.
Trailing returns across standard periods
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies in developed markets that are involved in the development of robotics and/or artificial intelligence. The fund is non-diversified.
Read more on BOTZ →Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →